hVIVO (LON:HVO) Shares Up 23% - Should You Buy?

hVIVO plc (LON:HVO - Get Free Report)'s stock price shot up 23% on Monday . The stock traded as high as GBX 11 ($0.15) and last traded at GBX 10.70 ($0.14). 24,253,932 shares changed hands during mid-day trading, an increase of 569% from the average session volume of 3,624,890 shares. The stock had previously closed at GBX 8.70 ($0.12).

Wall Street Analyst Weigh In

Separately, Shore Capital reissued a "buy" rating on shares of hVIVO in a research note on Friday, May 30th.

hVIVO Stock Performance

The company has a debt-to-equity ratio of 33.86, a current ratio of 1.61 and a quick ratio of 1.16. The stock's 50-day simple moving average is GBX 15.82 and its 200 day simple moving average is GBX 17.61. The stock has a market capitalization of £77.83 million, a P/E ratio of 4.54 and a beta of 0.97.

hVIVO (LON:HVO - Get Free Report) last released its quarterly earnings data on Thursday, April 10th. The company reported GBX 1.69 ($0.02) EPS for the quarter. hVIVO had a net margin of 25.96% and a return on equity of 47.93%. Research analysts expect that hVIVO plc will post 1.5492958 EPS for the current fiscal year.

About hVIVO

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.